Eli Lilly will provide drug candidates that PsychoGenics will evaluate for the treatment of neuropsychiatric disorders, according to a drug discovery and development agreement.
The agreement provides either party the option to exclusively develop any drug candidate emerging from this collaboration, with the nondeveloping party receiving milestones and royalties commensurate with the stage of development.
PsychoGenics' technologies combine in vivo behavioral expertise together with recent developments in robotics, computer vision, and bio/cheminformatics to evaluate drug candidates for potential utility across the spectrum of neuropsychiatric disease indications.